Gritstone Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Gritstone bio, Inc. (Nasdaq: GRTS) announced that its Board of Directors has granted nonqualified stock options to five new employees, allowing them to purchase 46,950 shares at an exercise price of $2.69, equivalent to the stock's closing price on December 6, 2022. These options are part of an inducement for employment and will vest over four years, with a fourth of them vesting after one year. This decision aligns with Nasdaq Listing Rule 5635(c)(4) and the company’s 2021 Employment Inducement Incentive Award Plan.
Positive
- Issuance of stock options demonstrates commitment to attracting talent.
- Stock options are standard practice to incentivize employees and align their interests with shareholders.
Negative
- None.
Details
News Market Reaction – GRTS
The recorded move for GRTS in the trading session of this news was -4.19%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
EMERYVILLE, Calif., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced that the company’s Board of Directors granted five employees nonqualified stock options to purchase an aggregate of 46,950 shares of its common stock with an exercise price of
The stock options will vest over a four-year period, with
About Gritstone bio
Gritstone bio, Inc. (Nasdaq: GRTS) is a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines. We leverage our innovative vectors and payloads to train multiple arms of the immune system to attack critical disease targets. Independently and with our collaborators, we are advancing a portfolio of product candidates to treat and prevent viral diseases and solid tumors in pursuit of improving patient outcomes and eliminating disease. www.gritstonebio.com
Gritstone Contacts
Investors:
George E. MacDougall
Director, Investor Relations & Corp Comms
Gritstone bio, Inc.
ir@gritstone.com
Media:
Dan Budwick
1AB
(973) 271-6085
dan@1abmedia.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.